Halozyme Therapeutics Inc. Stock
We can see a decrease in the price for Halozyme Therapeutics Inc.. Compared to yesterday it has lost -€0.680 (-1.170%).
With 19 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 70 € there is a positive potential of 21.87% for Halozyme Therapeutics Inc. compared to the current price of 57.44 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | -1.170% | -2.343% | -13.519% | 2.929% | -0.444% | 49.017% | 62.416% |
| United Therapeutics | 2.620% | 7.574% | 16.067% | 57.007% | 8.027% | 114.598% | 244.478% |
| Iovance Biotherapeutics Inc. | -5.130% | 38.824% | 104.338% | 29.037% | 88.659% | -23.294% | -84.170% |
| Ligand Pharmaceuticals | 3.910% | 5.780% | 8.929% | 69.444% | 10.241% | 172.971% | 48.599% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
News
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty
Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme